A growing community
Teresa Del Giudice is the 30,000th ESMO Member. In this interview she explains what motivated her to join the community.
Advanced genetic testing is largely inaccessible to cancer patients across Europe
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
“Green” prescribing may limit the environmental impact of oncology
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
When your patient is the global population
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Does AI hold the future of early cancer detection?
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged to implement innovation in cancer screening programmes
How can lung cancer prevention and treatment strategies be improved in resource-restricted settings?
The key to overcoming barriers to effective prevention and treatment in resource-restricted settings involves cooperation between multiple organisations, including medical societies, patient groups, pharmaceutical companies and regulatory agencies
Clean air is essential to prevent lung cancer
ESMO is contributing to making European Union legislation stricter on exposure limits for air pollution and asbestos to prevent new lung cancer cases
Patients as partners to address unmet needs in sarcoma
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
Cancer Control Principles
Early drug development: paving the way to patient-centred design
Adding precision to dose-finding in early-phase clinical trials has become critical in the immunotherapy era, and moving away from paradigms of the past has become mandatory